Skip to main content
Equibles

ATHE · Alterity Therapeutics Ltd · Investor Relations

Track ATHE — free

Use ATHE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ATHE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.37 -0.06 (-2.47%)
Rebalance outlook locked
Market Cap
$44.61M
Shares
18.21M
Volume · Oct 20 17.73K Avg daily vol (3M) 18.32K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-08-12 Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434 Event
2026-08-06 Alterity Therapeutics to Present at the Canaccord Genuity Growth Conference Conference
2026-07-30 Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update Event
2026-07-21 Alterity to Participate in the BTIG Biotechnology Conference Conference
2026-07-07 Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy Event
2026-06-09 Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy Event
2026-05-19 Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy Presentation
2026-05-11 Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy Event
2026-05-07 Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 Conference
2026-04-30 Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update Event
2026-04-27 Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy Event
2026-04-22 Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology Event
2026-04-17 Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors Event
2026-04-16 Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting Shareholder meeting
2026-04-15 Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy Event
2026-03-30 Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program Event
2026-03-09 Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit Event
2026-03-04 Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor Event
2026-03-02 Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments Event
2026-01-30 Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update Event
2026-01-21 Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 Shareholder meeting
2025-11-21 Chairman's Address 2025 Annual General Meeting Shareholder meeting
2025-11-21 AGM 2025 Presentation Presentation
2025-11-12 Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference Conference
2025-11-10 Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSAat the 36th International Symposium on the Autonomic Nervous System Event

Source: https://www.alteritytherapeutics.com/investors

Key facts CIK 1131343 CUSIP 02155X205 13F (30d) 4 filings 4 filers Visit website Investor relations